CAJ | 학술논문

目的：探讨参附注射液联合依达拉奉治疗进展性脑梗塞的临床疗效。方法整群选取该院于2012年4月-2014年1月收治的104例进展性脑梗塞患者为研究对象,根据其入院就诊顺序分成A、B两组。B组仅予以静脉滴注依达拉奉方案，A组在上述基础上联合参附注射液。行为期2~6个月随访，比对两组患者治疗前后美国国立卫生院卒中量表(NIHSS)评分、脑卒中神经功能缺损程度(NFDS)评分、Barthel指数评估结果及相关实验室指标变化情况。结果①治疗后，两组患者PTL指标均较治疗前明显降低，APTT指标则较治疗前明显提高，其中A组变化幅度大于B组(P<0.05)；②治疗后，两组患者各神经功能评分均较治疗前明显降低，Barthel指数则较治疗前显著提高，其中A组变化幅度大于B组(P<0.05)。结论对进展性脑梗塞患者予以依达拉奉联合参附注射液静脉滴注方案，疗效确切，值得临床推广。
목적：탐토삼부주사액연합의체랍봉치료진전성뇌경새적림상료효。방법정군선취해원우2012년4월-2014년1월수치적104례진전성뇌경새환자위연구대상,근거기입원취진순서분성A、B량조。B조부여이정맥적주의체랍봉방안，A조재상술기출상연합삼부주사액。행위기2~6개월수방，비대량조환자치료전후미국국립위생원졸중량표(NIHSS)평분、뇌졸중신경공능결손정도(NFDS)평분、Barthel지수평고결과급상관실험실지표변화정황。결과①치료후，량조환자PTL지표균교치료전명현강저，APTT지표칙교치료전명현제고，기중A조변화폭도대우B조(P<0.05)；②치료후，량조환자각신경공능평분균교치료전명현강저，Barthel지수칙교치료전현저제고，기중A조변화폭도대우B조(P<0.05)。결론대진전성뇌경새환자여이의체랍봉연합삼부주사액정맥적주방안，료효학절，치득림상추엄。
Objective To explore the clinical therapeutic effect of Shenfu injection combined with edaravone in treatment of pro-gressive cerebral infarction. Methods In our hospital from 2012 April to 2014 January were treated 104 of progressive cerebral in-farction patients as research object, according to hospital admission sequence were divided into A, B two groups. B group was treated only by intravenous injection of edaravone solution, the A group on the basis of the above combined with Shenfu injection. Followed-up 2-6 months, compared to American National Institutes of Health Stroke Scale (NIHSS) score, stroke the degree of neurological deficit (NFDS) score, result of Barthel index and laboratory index variation of patients in two groups before and after treatment. Results ①After treatment, patients with PTL index of two groups was significantly lower than before treatment, the APTT index was significantly improved, the changes of A group was greater than group B (P<0.05); ② After treatment, various neurological function score of two groups was significantly lower than those before treatment, while barthel index was significantly improved, the changes of which of group A was greater than that of the group B (P<0.05). Conclusion The curative effect of edar-avone combined with Shenfu injection scheme on patients with progressive cerebral infarction is accurate, and it is worth clinical promotion.